唑来膦酸治疗对绝经后骨质疏松症女性抑郁及生活质量的影响：一项临床试验研究。
The effects of zoledronic acid treatment on depression and quality of life in women with postmenopausal osteoporosis: A clinical trial study.
作者信息
Gokosmanoglu Feyzi, Varim Ceyhun, Atmaca Aysegul, Atmaca Mehmet Hulusi, Colak Ramis
机构信息
Department of Endocrinology, Sakarya University Research and Training Hospital, Sakarya, Turkey.
Department of Internal Medicine, Faculty of Medicine, Sakarya University, Sakarya, Turkey.
出版信息
J Res Med Sci. 2016 Nov 7;21:112. doi: 10.4103/1735-1995.193503. eCollection 2016.
BACKGROUND
Osteoporosis affects quality of life (QoL) and may lead to depression in women. The purpose of this study was to evaluate the effects of zoledronic acid (ZA) treatment on depression and QoL in women with postmenopausal osteoporosis (PO).
MATERIALS AND METHODS
A total of 88 newly diagnosed women with PO were included in this study. All patients were treated with once-yearly ZA (5 mg). A QoL questionnaire from the European Foundation for Osteoporosis and Beck Depression Inventory were given to patients at baseline and at 12 months. The results for baseline and post - 12 month were compared, and bone mineral density (BMD) levels were compared.
RESULTS
The consumption of once-yearly ZA (5 mg) treatment increases BMD at levels of lumbers 1-4 ( = 0.026), total Hip T score's value is same as femoral neck (P: 0,033). ZA 5 mg treatment also improved QoL ( = 0.001) and reduced depression ( = 0.001).
CONCLUSION
ZA treatment increases BMD levels and QoL while reducing depression. Once-yearly ZA (5 mg) may be considered for postmenopausal women as a first-line treatment.
背景
骨质疏松症会影响生活质量（QoL），并可能导致女性抑郁。本研究的目的是评估唑来膦酸（ZA）治疗对绝经后骨质疏松症（PO）女性抑郁和生活质量的影响。
材料与方法
本研究共纳入88例新诊断的PO女性患者。所有患者均接受每年一次的ZA（5mg）治疗。在基线和12个月时向患者发放来自欧洲骨质疏松症基金会的生活质量问卷和贝克抑郁量表。比较基线和12个月后的结果，并比较骨密度（BMD）水平。
结果
每年一次的ZA（5mg）治疗可提高第1-4腰椎水平的骨密度（=0.026），全髋T值与股骨颈相同（P：0.033）。5mg ZA治疗还改善了生活质量（=0.001）并减轻了抑郁（=0.001）。
结论
ZA治疗可提高骨密度水平和生活质量，同时减轻抑郁。每年一次的ZA（5mg）可作为绝经后女性的一线治疗方案。
Zotero 插件